Zobrazeno 1 - 10
of 50
pro vyhledávání: ''
Autor:
Barbara Alicja Jereczek-Fossa, Giulia Marvaso, Massimo Sarra Fiore, Luca Bergamaschi, Fabrizio Mastrilli, Daniela Alterio, Giulia Corrao, Gabriella Pravettoni, Mattia Zaffaroni, Roberta Lazzari, Giammaria Bufi, Roberto Orecchia, Maria Cristina Leonardi, Federica Cattani
Publikováno v:
Tumori
Objective: During 2020, medical clinical activities were dramatically modified by the coronavirus disease 2019 (COVID-19) emergency. We aim to evaluate the impact of COVID-19 on radiotherapy (RT) practice in a hub cancer center. Methods: Retrospectiv
Autor:
Francesco Cellini, Emanuele Rocco Villani, Stefania Manfrida, Giuditta Chiloiro, Maria Antonietta Gambacorta, Andrea Bellieni, Giuseppe Colloca, Luca Boldrini, Vincenzo Valentini
Publikováno v:
Tumori Journal. 107:26-31
Background: Elderly patients are often excluded from advanced treatments owing to clinical complexity or frailty. Magnetic resonance–guided radiotherapy (MRgRT) represents a new frontier of radiotherapy delivery that can play an important role in t
Autor:
Maximiliano Ribeiro Guerra, Annalisa Trama, Maria do Rosário Dias de Oliveira Latorre, Laura Botta, Gemma Gatta, Luana F. Tanaka, Maria Teresa Bustamante-Teixeira
Publikováno v:
Tumori Journal. 105:22-30
Introduction: Rare cancers are a challenge for clinical practice as well as for epidemiology and public health. Studies on this subject are few and limited to the study of cases with scarce epidemiologic information. This study aimed to evaluate the
Autor:
Carlo Resteghini, Paolo Bossi, Carla Ripamonti, Patrizia Giannatempo, Nicoletta Zilembo, Andrea Necchi, Laura Ferrari, M.A. Pessi
Publikováno v:
Tumori Journal. 101:692-696
Aims and Background There is a paucity of data regarding the incidence, intensity, and treatment of nausea and vomiting during the intercycle periods of chemotherapy (CHT). The aims of the study were to assess the incidence and intensity of intercycl
Autor:
Maurizio De Cicco, Marco Merlano, Rodolfo Passalacqua, Sergio Crispino, Emanuela Omodeo Salè, Massimo Di Maio, Caterina Caminiti, Carmelo Iacono, Fabrizio Nicolis, Vittorina Zagonel, Annamaria Mancuso, Carmine Pinto, Luisa Fioretto, Francesco Perrone, Alessandro Comandone, Sandro Spinsanti, Giuseppe Aprile, Roberto Labianca, Roberto Bordonaro, Francesco Di Costanzo, Paolo Marchetti, Stefania Gori, Giovanni Micallo, Aiom
Publikováno v:
Tumori Journal. 102:e25-e27
Cancer care involves many ethical issues. The need for more patient-centered healthcare together with the improved empowerment of every person diagnosed with cancer have been transposed by the Italian Association of Medical Oncology (AIOM) and eventu
Autor:
Weruska Bacelli, Monia Duca, Katia Marilungo, Stefano Cascinu, Giusi Giacomini, Rosa Rita Silva, Ettore Tito Menichetti, Zelmira Ballatore, Rossana Berardi, Massimo Marcellini
Publikováno v:
Tumori Journal. 101:621-625
Aims and Background Cancer is a disease that has far-reaching consequences for patients and their families. The present study targets unmet caregiver needs so that better support can be provided and planned for. Methods The first phase of the study w
Autor:
Saverio Cinieri, M.C. Chetri, Angelo Nacci, Nicola Calvani, Palma Fedele, E. Mazzoni, Laura Orlando, Chiara Caliolo, A. Marino, Annamaria Quaranta, Pasqualinda Ferrara, Margherita Cinefra, Paola Schiavone, Francesco Sponziello, Stefania Eufemia Lutrino, P. Rizzo, M. D'Amico
Publikováno v:
Tumori Journal. 101:524-528
Aims and background Few data describe the activity of panitumumab after cetuximab-irinotecan-based regimen failure in patients with KRAS wild-type metastatic colorectal cancer (WT MCRC). Methods The aim of this study is to assess if panitumumab has s
Autor:
Lorenza Rimassa, Armando Santoro, Antonio Gasbarrini, Bruno Daniele, Camillo Porta, Domenico Germano, Maria Lamar, Stefania Salvagni, Terri Goldberg, Gianluca Masi, Giovanni Abbadessa
Publikováno v:
Tumori Journal. 101:139-143
In the last decades the management of hepatocellular carcinoma (HCC) has undergone significant changes following the introduction of novel therapies such as sorafenib, which have improved patient survival. Nevertheless, HCC is still the third most co
Autor:
Maria Domenica Iuvaro, Tiziana Carucci, Gabriella De Benedetta, Carlo Chiorri, Marco Romeo, Wissya Santoni, Gabriella Morasso, Valentina Clavarezza, Valentina Belbusti, Silvia D'Ovidio, Silvia Di Leo, Angela Piattelli, Anita Caruso
Publikováno v:
Tumori Journal. 101:131-137
Aims and Background This study is aimed at evaluating the effectiveness of a physician-centered communication skills training program on cancer patient anxiety levels. Methods and Study design In this quasi-experimental study, physicians from 9 units
Publikováno v:
Tumori Journal. 101:e115-e117
The malignant behavior of non-small cell lung cancer (NSCLC) is caused by different driver mutations, which may include alterations in the epidermal growth factor receptor (EGFR) signaling pathway. Activating mutations in exons 19 or 21 of EGFR in NS